Ancora Advisors LLC raised its position in Varian Medical Systems, Inc. (NYSE:VAR) by 18.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 57,286 shares of the medical equipment provider’s stock after acquiring an additional 8,967 shares during the period. Ancora Advisors LLC owned about 0.06% of Varian Medical Systems worth $7,026,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. Element Capital Management LLC acquired a new position in Varian Medical Systems in the 1st quarter valued at $507,000. Natixis grew its holdings in Varian Medical Systems by 262.7% in the 1st quarter. Natixis now owns 50,748 shares of the medical equipment provider’s stock valued at $6,224,000 after buying an additional 36,755 shares in the last quarter. Ostrum Asset Management acquired a new position in Varian Medical Systems in the 1st quarter valued at $618,000. The Manufacturers Life Insurance Company grew its holdings in Varian Medical Systems by 5.7% in the 1st quarter. The Manufacturers Life Insurance Company now owns 98,140 shares of the medical equipment provider’s stock valued at $12,036,000 after buying an additional 5,322 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new position in Varian Medical Systems in the 1st quarter valued at $1,288,000. Institutional investors own 93.51% of the company’s stock.
A number of research analysts have commented on the company. TheStreet raised Varian Medical Systems from a “c” rating to a “b” rating in a report on Wednesday, April 25th. ValuEngine raised Varian Medical Systems from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research raised Varian Medical Systems from a “hold” rating to a “buy” rating and set a $142.00 price objective on the stock in a report on Tuesday, March 13th. Finally, Royal Bank of Canada set a $115.00 target price on Varian Medical Systems and gave the company a “hold” rating in a research report on Tuesday, April 10th. Two analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $115.13.
NYSE:VAR opened at $121.09 on Wednesday. Varian Medical Systems, Inc. has a fifty-two week low of $95.23 and a fifty-two week high of $130.29. The firm has a market cap of $11.18 billion, a PE ratio of 33.64, a P/E/G ratio of 3.39 and a beta of 0.85.
Varian Medical Systems (NYSE:VAR) last issued its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $1.15 EPS for the quarter, topping the consensus estimate of $1.04 by $0.11. Varian Medical Systems had a net margin of 4.77% and a return on equity of 27.99%. The firm had revenue of $729.90 million for the quarter, compared to analyst estimates of $685.86 million. During the same period in the prior year, the business posted $0.89 EPS. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. sell-side analysts anticipate that Varian Medical Systems, Inc. will post 4.51 earnings per share for the current year.
About Varian Medical Systems
Varian Medical Systems, Inc designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through two segments, Oncology Systems and Varian Particle Therapy. The Oncology Systems segment provides hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy.
Receive News & Ratings for Varian Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.